These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 7809953)

  • 61. Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine D₂ agonist therapy: part 2.
    Blum K; Chen TJ; Morse S; Giordano J; Chen AL; Thompson J; Allen C; Smolen A; Lubar J; Stice E; Downs BW; Waite RL; Madigan MA; Kerner M; Fornari F; Braverman ER
    Postgrad Med; 2010 Nov; 122(6):214-26. PubMed ID: 21084796
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Medications development at the National Institute on Drug Abuse: focus on cocaine.
    Johnson DN; Vocci FJ
    NIDA Res Monogr; 1993; 135():57-70. PubMed ID: 8289904
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Single-dose bromocriptine reverses cocaine craving.
    Dackis CA; Gold MS; Sweeney DR; Byron JP; Climko R
    Psychiatry Res; 1987 Apr; 20(4):261-4. PubMed ID: 3602212
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Mixed κ/μ partial opioid agonists as potential treatments for cocaine dependence.
    Bidlack JM
    Adv Pharmacol; 2014; 69():387-418. PubMed ID: 24484983
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials.
    Kishi T; Matsuda Y; Iwata N; Correll CU
    J Clin Psychiatry; 2013 Dec; 74(12):e1169-80. PubMed ID: 24434105
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Dopamine partial receptor agonists reduce ethanol intake in the rat.
    Bono G; Balducci C; Richelmi P; Koob GF; Pulvirenti L
    Eur J Pharmacol; 1996 Feb; 296(3):233-8. PubMed ID: 8904074
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The dopamine D(2) partial agonist and antagonist terguride decreases heroin self-administration on fixed- and progressive-ratio schedules.
    Zhang D; Wang X; Xiang X; Chen H; Zhang J; Su Q; Hao W
    Pharmacol Biochem Behav; 2010 Dec; 97(2):222-6. PubMed ID: 20705086
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pergolide mesylate treatment of cocaine withdrawal.
    Malcolm R; Hutto BR; Phillips JD; Ballenger JC
    J Clin Psychiatry; 1991 Jan; 52(1):39-40. PubMed ID: 1988417
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Chronic neuropharmacology of cocaine: progress in pharmacotherapy.
    Gawin FH
    J Clin Psychiatry; 1988 Feb; 49 Suppl():11-6. PubMed ID: 3276669
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The physiology of cocaine craving and 'crashing'.
    Dackis CA; Gold MS; Sweeney DR
    Arch Gen Psychiatry; 1987 Mar; 44(3):298-300. PubMed ID: 3827524
    [No Abstract]   [Full Text] [Related]  

  • 72. Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents.
    Newman AH; Grundt P; Nader MA
    J Med Chem; 2005 Jun; 48(11):3663-79. PubMed ID: 15916415
    [No Abstract]   [Full Text] [Related]  

  • 73. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence.
    Le Foll B; Goldberg SR
    J Pharmacol Exp Ther; 2005 Mar; 312(3):875-83. PubMed ID: 15525797
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Neural substrates of psychostimulant withdrawal-induced anhedonia.
    D'Souza MS; Markou A
    Curr Top Behav Neurosci; 2010; 3():119-78. PubMed ID: 21161752
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pergolide mesylate in Parkinson's disease treatment.
    Pezzoli G; Canesi M; Pesenti A; Mariani CB
    J Neural Transm Suppl; 1995; 45():203-12. PubMed ID: 8748627
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Treatment of cocaine abuse: pharmacotherapy.
    Kleber HD
    Ciba Found Symp; 1992; 166():195-200; discussion 200-6. PubMed ID: 1638913
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Bromocriptine and amantadine in cocaine detoxification.
    Giannini AJ; Folts DJ; Feather JN; Sullivan BS
    Psychiatry Res; 1989 Jul; 29(1):11-6. PubMed ID: 2672061
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Psychostimulants: Basic and Clinical Pharmacology.
    McCreary AC; Müller CP; Filip M
    Int Rev Neurobiol; 2015; 120():41-83. PubMed ID: 26070753
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pharmacologically-mediated reactivation and reconsolidation blockade of the psychostimulant-abuse circuit: a novel treatment strategy.
    Lee TH; Szabo ST; Fowler JC; Mannelli P; Mangum OB; Beyer WF; Patkar A; Wetsel WC
    Drug Alcohol Depend; 2012 Jul; 124(1-2):11-8. PubMed ID: 22356892
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Dopamine receptor partial agonists could address the duality of cocaine craving.
    Childress AR; O'Brien CP
    Trends Pharmacol Sci; 2000 Jan; 21(1):6-9. PubMed ID: 10637646
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.